ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

(OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and ...

(OTC: VCNX) (“Vaccinex” or the“Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and ...

Cellular and non-cellular components of the tumor microenvironment (TME) are emerging as key regulators of primary tumor progression, organ-specific metastasis, and therapeutic response. In the era of ...

Canonical Wnt signalling in PDGFRα-expressing cells is a critical regulator of astrogliosis and axon regeneration following CNS injury.

Parkinson’s disease (PD) is characterized by damage to the ascending nigrostriatal pathway, including progressive loss of dopaminergic (DA) neurons in the substantia nigra (SN) and axon terminals in ...